Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116962 | 0.89 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4122377 | 0.85 | SLC6A2 (0.80) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4115959 | 0.85 | SLC6A2 (0.91) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4112198 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4122232 | 0.84 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4117031 | 0.83 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4118155 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4112652 | 0.83 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4104734 | 0.82 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4120598 | 0.82 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1828121-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064336-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | SLC6A2 5/4885SLC6A4 36/4885SLC6A3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.